Enhertu is a HER2-directed antibody and topoisomerase inhibitor ... assessed by blinded independent central review based on Response Evaluation Criteria in Solid Tumors v1.1 In the HER2-low population ...

More common side effects in people receiving Enhertu for breast cancer, NSCLC, or solid tumors include: Mild side effects that may occur from receiving Enhertu may vary depending on the condition ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy ... FDA earlier this year for all HER2-positive solid tumours, regardless of their location ...

The companies’ sBLA was seeking approval for Enhertu to treat unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Enhertu is a HER2-directed antibody and topoisomerase ... central review based on Response Evaluation Criteria in Solid Tumors v1.1 In the HER2-low population, findings showed treatment with ...